DrugPatentWatch Database Preview

Akorn Company Profile

AKORN has one hundred and sixty-six approved drugs.

There is one US patent protecting AKORN drugs. There are three tentative approvals on AKORN drugs.

There are two patent family members on AKORN drugs in two countries and one hundred and forty-seven supplementary protection certificates in twelve countries.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Akorn	IC-GREEN	indocyanine green	INJECTABLE;INJECTION	011525-001	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes		➤ Sign Up				➤ Sign Up
Akorn	HYDROMORPHONE HYDROCHLORIDE	hydromorphone hydrochloride	INJECTABLE;INJECTION	078261-001	Apr 14, 2010	AP	RX	No	No		➤ Sign Up				➤ Sign Up
Akorn	HEPARIN SODIUM	heparin sodium	INJECTABLE;INJECTION	017486-001	Approved Prior to Jan 1, 1982		DISCN	No	No		➤ Sign Up				➤ Sign Up
Akorn Inc	CEFTRIAXONE	ceftriaxone sodium	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS	065305-002	Jan 11, 2008	AP	RX	No	No		➤ Sign Up				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Akorn	ALFENTA	alfentanil hydrochloride	INJECTABLE;INJECTION	019353-001	Dec 29, 1986	4,167,574	➤ Sign Up
Akorn	SUFENTA PRESERVATIVE FREE	sufentanil citrate	INJECTABLE;INJECTION	019050-001	May 4, 1984	3,998,834	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2008014036	➤ Sign Up
European Patent Office	2043601	➤ Sign Up
Country	Document Number	Estimated Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C/GB98/031	United Kingdom	➤ Sign Up	PRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412
80016	Netherlands	➤ Sign Up	PRODUCT NAME: LEVOFLOXACINE, DESGEWENST IN DE VORM VAN EEN SOLVAAT, IN HET BIJZONDER LEVOFLOXACINE-HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: RVG 21810 - RVG 21812 19971209; FIRST REGISTRATION: GB 13402/0011 - 13402/0013 19970606
C/GB01/039	United Kingdom	➤ Sign Up	PRODUCT NAME: ZOLEDRONIC ACID OPTIONALLY IN THE FORM OF A SALT THEREOF; NATIONAL REGISTRATION NO/DATE: EU/1/01/176/001-003 20010320; FIRST REGISTRATION: CH 55463 20001128
2008006	Lithuania	➤ Sign Up	PRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.